Program
G(M1) Ganglioside
Its studies are mostly in Parkinson Disease, led by Qilu Pharmaceutical.
Drug pageG(M1) Ganglioside: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since May 19, 20252 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 22 open or running | phase 3since May 19, 2025 | May 19, 2025 | Mar 2028phase 2 · NCT07585565 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2025First study: phase 3 study in Chemotherapy-induced Peripheral Neuropathy (CIPN)First studyNCT06994507 · 352 planned · China
- Apr 27, 2026Phase 2 study in Parkinson DiseaseNCT07585565 · 276 planned
Ahead
- Mar 2028Primary completion: phase 2 study in Parkinson DiseaseNCT07585565
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07585565Parkinson Disease | 2 | Not yet recruiting | Mar 2028 | 276 |
| NCT06994507Chemotherapy-induced Peripheral Neuropathy (CIPN) · China | 3 | Recruiting | Sep 2026 | 352 |
How it is read
Names in the registry
- “GM1”, 4 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.